Glycine Antagonist in Neuroprotection for Patients With Acute Stroke: GAIN Americas: A Randomized Controlled Trial
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CONTEXT: Elucidation of the ischemic cascade has helped stimulate development of neuroprotective drugs aimed at limiting brain injury in the hours following an ischemic stroke. To date, none of these drugs has shown clinical efficacy. OBJECTIVE: To examine the efficacy of gavestinel (GV150526), an antagonist of the glycine site of the N-methyl-D-aspartate receptor, as a neuroprotective therapy for acute ischemic stroke when administered within 6 hours of symptom onset. DESIGN: The Glycine Antagonist in Neuroprotection (GAIN) Americas trial, a randomized, double-blind placebo-controlled trial with enrollment from April 1998 to October 1999. SETTING: One hundred thirty-two hospital centers across the United States and Canada. PATIENTS: The primary efficacy population consisted of 1367 ischemic stroke patients with a predefined level of limb weakness and functional independence prior to stroke, stratified at randomization by age (</=75 vs >75 years) and initial stroke severity (National Institutes of Health [NIH] Stroke Scale scores of 2-5, 6-13, or >/=14). INTERVENTION: Patients were randomly assigned to receive an intravenous loading dose (800 mg) plus 5 maintenance doses (200 mg every 12 hours) of gavestinel (n = 701) or placebo (n = 666) for 3 days. MAIN OUTCOME MEASURE: Functional capability at 3 months, measured by the Barthel Index (BI), with scores trichotomized as dead/0-55, 60-90, and 95-100, compared between the gavestinel and placebo groups. RESULTS: Treatment groups were well matched for baseline characteristics. For each group, median NIH Stroke Scale was 12, median age was 72 years, and median time to treatment was 5.2 hours. No statistically significant improvement on the 3-month BI trichotomy was demonstrated for gavestinel (P =.79). The proportion who were functionally independent (BI score = 95-100) was 39% in the gavestinel group and 37% in the placebo group. No statistically significant difference in 3-month survival was observed using Kaplan-Meier curves (P =.11). No other secondary end point suggested an advantage for gavestinel. Among the 333 patients (24%) who received recombinant tissue-type plasminogen activator, there was also no benefit for gavestinel (P =.53). There were no serious safety issues. CONCLUSION: In this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,335
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Classification and natural history of clinically identifiable subtypes of cerebral infarction
Bamford, J., Sandercock, P., Dennis, M., Warlow, C., & Burn, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)93206-o · Cited by 3,294 · cited 4×
“Kent Cooper, MD, Mary Keane, RN; Royal Columbia Hospital, New Westminster, British Columbia (15): Joseph Haegert, MD; Hamilton Health Sciences Corp General Division, Hamilton, Ontario (14): Robert Duke, MD, Wes Oczkowski, MD, J.”
BackgroundInfluentialChi-Square Tests with One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure
Mantel, N. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500879 · Cited by 2,897
Thresholds in cerebral ischemia - the ischemic penumbra.
Astrup, J., Siesjö, B. K., & Symon, L. (1981) · Stroke · doi:10.1161/01.str.12.6.723 · Cited by 2,820
Analysis of Categorical Data by Linear Models
Grizzle, J. E., Starmer, C. F., & Koch, G. G. (1969) · Biometrics · doi:10.2307/2528901 · Cited by 1,503
Viability thresholds and the penumbra of focal ischemia
Hossmann, K. (1994) · Annals of Neurology · doi:10.1002/ana.410360404 · Cited by 1,370 · cited 5×
“Brian Wolfe, PharmD, BCPS; Boston Medical Center, Boston, Mass (3): Viken Babikian, MD, Eloise Licata-Gehr, RN, MS, Carlos Kase, MD; Iowa Methodist Medical Center, Des Moines (3): Calvin Hansen, MD, Deb Burnett, RN; Massachussetts General Hospital, Boston (3): Walter Koroshetz, MD; Mt Sinai Medical Center, New York, N…”
BackgroundInfluentialImproved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.
Lyden, P., Brott, T., Tilley, B., Welch, K. M., Mascha, E. J., Levine, S., Haley, E. C., Grotta, J., & Marler, J. (1994) · Stroke · doi:10.1161/01.str.25.11.2220 · Cited by 1,285
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
The Stroke Impact Scale Version 2.0: Evaluation of Reliability, Validity, and Sensitivity to Change
Duncan, P. W., Wallace, D., Lai, S. M., Johnson, D., Embretson, S., & Laster, L. J. (1999) · Stroke · doi:10.1161/01.str.30.10.2131 · Cited by 1,180
Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials
Sulter, G., Steen, C., & Keyser, J. D. (1999) · Stroke · doi:10.1161/01.str.30.8.1538 · Cited by 1,117
Stroke rehabilitation: analysis of repeated Barthel index measures.
Granger, C. V., Dewis, L. S., Peters, N., Sherwood, C. C., & Barrett, J. E. (1979) · PubMed · Cited by 600
Lees, K. R., Asplund, K., Carolei, A., Davis, S. M., Diener, H.-C., Kaste, M., Orgogozo, J.-M., & Whitehead, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02326-6 · Cited by 309
Wahlgren, N. G., MacMahon, D. G., De Keyser, J., Indredavik, B., & Ryman, T. (1994) · Cerebrovascular Diseases · doi:10.1159/000108483 · Cited by 279
A Randomized Efficacy Trial of Citicoline in Patients With Acute Ischemic Stroke
Clark, W. M., Williams, B. J., Selzer, K. A., Zweifler, R. M., Sabounjian, L. A., & Gammans, R. E. (1999) · Stroke · doi:10.1161/01.str.30.12.2592 · Cited by 232
Lubeluzole Treatment of Acute Ischemic Stroke
Grotta, J. (1997) · Stroke · doi:10.1161/01.str.28.12.2338 · Cited by 193
Termination of Acute Stroke Studies Involving Selfotel Treatment
Davis, S. M., Albers, G. W., Diener, H.-C., Lees, E. R., & Norris, J. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62166-6 · Cited by 192
Wahlgren, N. G., Ranasinha, K. W., Rosolacci, T., Franke, C. L., van Erven, P. M. M., Ashwood, T., & Claesson, L. (1999) · Stroke · doi:10.1161/01.str.30.1.21 · Cited by 178
Treatment of Acute Ischemic Stroke With Piracetam
De Deyn, P. P., De Reuck, J., Deberdt, W., Vlietinck, R., & Orgogozo, J.-M. (1997) · Stroke · doi:10.1161/01.str.28.12.2347 · Cited by 154 · cited 2×
“75 y Gavestinel 31 13 (42) 11 (35) 7 (23) .”
Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic Stroke
Diener, H. C. (1998) · Cerebrovascular Diseases · doi:10.1159/000015847 · Cited by 119
Cervene (Nalmefene) in Acute Ischemic Stroke
Clark, W. M., Raps, E. C., Tong, D., & Kelly, R. E. (2000) · Stroke · doi:10.1161/01.str.31.6.1234 · Cited by 97
Bordi, F., Pietra, C., Ziviani, L., & Reggiani, A. M. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6442 · Cited by 91
The Effects of Lifarizine in Acute Cerebral Infarction: A Pilot Safety Study
Squire, I. B., Lees, K. R., Pryse-Phillips, W. E. M., KERTESZ, A. E., & Bamford, J. (2007) · Cerebrovascular Diseases · doi:10.1159/000108016 · Cited by 47
Clark, W. M., Ertag, W., Orrechio, E., & Raps, E. C. (1999) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/s1052-3057(99)80071-8 · Cited by 24
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.181486 · Cited by 2,475
Banks, J. L., & Marotta, C. A. (2007) · Stroke · doi:10.1161/01.str.0000258355.23810.c6 · Cited by 2,253
Metadata
- Authors
- Sacco, R. L., DeRosa, J. T., Haley, Jr., Levin, B., Ordronneau, P., Phillips, S. J., Rundek, T., Snipes, R. G., Thompson, J. L. P., & for the GAIN Americas Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-04-04
- Volume
- 285
- Issue
- 13
- Pages
- 1719
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2131673806
- Cited by
- 283
- References
- 27
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.